New tools for quantifying HIV-1 reservoirs: Plasma RNA single copy assays and beyond

Current HIV/AIDS Reports

Volumn 9, Issue 1, 2012, Pages 91-100

  Hilldorfer, Benedict B ^a   Cillo, Anthony R ^a   Besson, Guillaume J ^a   Bedison, Margaret Anne ^a   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

HIV quantification; HIV reservoirs; HIV treatment intensification; Residual viremia; Single copy assay; Ultrasensitive PCR

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTERLEUKIN 7; PROGRAMMED DEATH 1 LIGAND 1; VIRUS DNA; VIRUS RNA;

CD34 CELL; CD4+ T LYMPHOCYTE; CELL TYPE; DNA DETERMINATION; GENE SEQUENCE; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOCOMPETENT CELL; INTESTINE LYMPHATIC TISSUE; NONHUMAN; PROCESS OPTIMIZATION; REPRODUCIBILITY; RESERVOIR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE COPY ASSAY; VIREMIA; VIRUS GENOME; BLOOD; DISEASE CARRIER; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIROLOGY;

DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIREMIA;

EID: 84858982531     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-011-0104-6     Document Type: Review

References (59)

1. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese Jr L, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282(17):1627-32. (Pubitemid 29513968)
2. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3(4):e46.
3. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA. 2001;286(2):171-9. (Pubitemid 32640848)
4. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(2):179-83.
5. Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS. 2000;14(3):243-9. (Pubitemid 30132918)
6. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS. 2000;14 (18):2805-12. (Pubitemid 32042743)
7. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41(10):4531-6. (Pubitemid 37259753)
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123-6.
9. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science. 1996;271(5255):1582-6. (Pubitemid 26097216)
10. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373(6510):117-22.
11. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986;233(4760):215-9.
12. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387(6629):188-91. (Pubitemid 27209434)
13. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387(6629):183-8. (Pubitemid 27209433)
14. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295-300. (Pubitemid 27495742)
15. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278 (5341):1291-5. (Pubitemid 27495741)
16. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA. 2008;105(10):3879-84. (Pubitemid 351723493)
17. Pascual-Pareja JF, Martinez-Prats L, Luczkowiak J, Fiorante S, Rubio R, Pulido F, et al. Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy. J Clin Microbiol. 2010;48(5):1911-2.
18. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2010;24(18):2803-8.
19. Gandhi RT BR, Aga E, Albrecht M, Demeter L, Bastow B, Siliciano R, Siliciano J, Eron J, ATCG A5173. No evidence for decay in the latent reservoir in HIV-infected patients receiving intensive enfuvirtide-containing ART. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
20. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010. doi:10.1371/journal. pmed/1000321.
21. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204(1):135-8.
22. Havlir DV, Koelsch KK, Strain MC, Margot N, Lu B, Ignacio CC, et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofo-vir or stavudine. J Infect Dis. 2005;191(7):1164-8. (Pubitemid 40404376)
23. Haim-Boukobza S, Morand-Joubert L, Flandre P, Valin N, Fourati S, Sayon S, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS. 2011;25(3):341-4.
24. McKinnon JE, Arribas JR, Pulido F, Delgado R, Mellors JW. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS. 2006;20(18):2331-5. (Pubitemid 44789535)
25. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296(7):806-14. (Pubitemid 44223104)
26. Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, Margolis DM, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis. 2009;199(6):866-71.
27. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16(4):460-5.
28. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2009;106(23):9403-8.
29. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ Tcell response. J Infect Dis. 2011;203(7):960-8.
30. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50(6):912-9.
31. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24(16):2451-60.
32. Gutierrez C DL, Hernandez-Novoa B, Vallejo A, Page C, Lorente R, Madrid N, Palmer S, Munoz-Fernandez MA, Moreno S. Effect of the intensification with a CCR5-antagonist on the decay of the HIV-1 latent reservoir and residual viremia. 17th Conference on Retroviruses & Opportunistic Infections; San Francisco; 2010.
33. Hilldorfer B LC, McKinnon J, Coombs B, Tenorio A, Fox L, Gandhi R, Ribauldo H, Currier J, Gulick R, Wilkins TJ, Mellors JW. Effects of Maraviroc (MVC) on residual low-level viremia in patients on suppressive Antiretroviral Therapy (ART): Results from ACTG 5256. International AIDS Association, Rome; 2011.
34. Hunt PW SN, Hayes T, Dahl V, Somsouk M, Funderburg N, Landay AL, Adeyemi O, Shafer R, Clagett B, Rodriguez B, Martin JN, Shacklett B, Palmer S, Lederman MM, Deeks SG The immunomodulatory effects of Maraviroc intensification among ART-suppressed patients with incomplete CD4 recovery. 18th Conference for Retroviruses and Opportunistic Infections; San Francisco; 2011
35. Wilkin TJ LC, Landay A, Ribaudo H, McKinnon J, Gandhi R, Mellors J, Currier J, Gulick R. Maraviroc (MVC) intensification for suboptimal CD4+ response despite sustained virologic suppression: ACTG 5256. Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
36. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77(20):11212-9. (Pubitemid 37204311)
37. Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, et al. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010;11(6):312-24.
38. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200(6):984-90.
39. Dinoso JB, Kim SY, Siliciano RF, Blankson JN. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis. 2008;47(1):102-4. (Pubitemid 351920594)
40. Mens H, Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol. 2010;84(24):12971-81.
41. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008;197(3):411-9. (Pubitemid 351263423)
42. Liszewski MK Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods. 2009;47(4):254-60.
43. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15 (8):893-900.
44. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43 (1):406-13. (Pubitemid 40096331)
45. Kearney M SJ, Yu S, Shao W, O'Shea A, Rehm C, Poethke C, Mellors J, Coffin J, Maldarelli F. The genetic diversity of HIV-1 in plasma persists despite suppression with ART. Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
46. Rothberg JM, Leamon JH. The development and impact of 454 sequencing. Nat Biotechnol. 2008;26(10):1117-24.
47. Jabara CJC, Anderson J, Swanstrom R. Accurate sampling and deep sequencing HIV-1 protease using primer ID. Conference on Retroviruses and Opportunistic Infections; Boston; 2011.
48. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ Tcells. J Virol. 2006;80(13):6441-57. (Pubitemid 43927447)
49. Anderson JA, Archin NM, Ince W, Parker D, Wiegand A, Coffin JM, et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol. 2011;85(10):5220-3.
50. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol. 2005;304:3-15.
51. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science. 1988;242 (4880):919-22. (Pubitemid 19015253)
52. Kitano K, Abboud CN, Ryan DH, Quan SG, Baldwin GC, Golde DW. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells. Blood. 1991;77(8):1699-705.
53. Ruiz ME, Cicala C, Arthos J, Kinter A, Catanzaro AT, Adelsberger J, et al. Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. J Immunol. 1998;161(8):4169-76. (Pubitemid 28468998)
54. Steinberg HN, Crumpacker CS, Chatis PA. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol. 1991;65(4):1765-9.
55. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell JT, Bixby D, Savona MR, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med. 2010;16(4):446-51.
56. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.
57. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, et al. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol. 2007;81(22):12145-55. (Pubitemid 350085830)
58. DaFonseca S. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway. In: Them TaCHRaStC, editor. International AIDS Society, Rome; 2011.
59. Josefsson L, King MS, Makitalo B, Brannstrom J, Shao W, Maldarelli F, et al. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci USA. 2011;108(27):11199- 11204.